EMVision’s promising results from stroke imaging

Brain imaging technology company EMVision Medical Devices has announced promising clinical trial results from a patient study of its haemorrhagic stroke detection algorithm.

The algorithm, dubbed ‘blood or not’, is a critical part of the microwave imaging system the company is developing under a grant from the Australian Stroke Alliance, to be fitted to point of care ambulances.

Simulations based on real data from 15 patients was used to accelerate AI algorithm development, with the results to be published this month in the International Journal of Stroke as part of the 15th World Stroke Congress being held in Toronto, Canada.

The tests correctly identified all five haemorrhagic stroke patients as well as the other patients as being without haemorrhage.

Imaging is used to rule out bleeding in stroke care, which is a contraindication to the administration of intravenous tPA which is used to restore blood flow to the brain in stroke patients.

EMVision will now move to Stage 2 testing which will test the full range of AI algorithms used in the company’s microwave imaging system.

Co-Chair of the stroke alliance Professor Geoffrey Donnan said: “The identification of blood is an important prerequisite for therapeutic decision making in acute stroke management.

“These early results are encouraging and the lightweight nature of the EMV device makes it ideally suited to the prehospital stroke environment.”

Further reading:
EMVision named as second stroke imaging developer
Browse @AuManufacturing’s coverage of EMVision Medical Devices here.

Picture: EMVision